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Mast cells (MCs) have been shown to release their nuclear DNA and subsequently form 
mast cell extracellular traps (MCETs) comparable to neutrophil extracellular traps, which 
are able to entrap and kill various microbes. The formation of extracellular traps is asso-
ciated with the disruption of the nuclear membrane, which leads to mixing of nuclear 
compounds with granule components and causes the death of the cell, a process called 
ETosis. The question arises why do MCs release MCETs although they are very well 
known as multifunctional long-living sentinel cells? MCs are known to play a role during 
allergic reactions and certain parasitic infections. Nonetheless, they are also critical com-
ponents of the early host innate immune response to bacterial and fungal pathogens: 
MCs contribute to the initiation of the early immune response by recruiting effector cells 
including neutrophils and macrophages by locally releasing inflammatory mediators, 
such as TNF-α. Moreover, various studies demonstrate that MCs are able to eliminate 
microbes through intracellular as well as extracellular antimicrobial mechanisms, includ-
ing MCET formation similar to that of professional phagocytes. Recent literature leads 
to the suggestion that MCET formation is not the result of a passive release of DNA and 
granule proteins during cellular disintegration, but rather an active and controlled pro-
cess in response to specific stimulation, which contributes to the innate host defense. 
This review will discuss the different known aspects of the antimicrobial activities of 
MCs with a special focus on MCETs, and their role and relevance during infection and 
inflammation.
Keywords: MCeT, extracellular traps, mast cell, neutrophil, innate immunity, antimicrobial activity, phagocytosis, 
degranulation
inTRODUCTiOn
Mast cells (MCs) have become famous for their role in type I hypersensitivity reactions. Better 
known as IgE-mediated allergic reactions, this MC response is induced after multivalent cross-
linkage of antigens with antigen-specific IgE, which then bind to high-affinity IgE receptors 
(Fc∈RI) on the cellular surface (1–3). For a long time, MCs have been underestimated and mainly 
known for their role as mediators in the early and acute phases of allergic reactions as well as 
their activation during certain parasitic infections (4). Indeed, they hold a multitude of very 
important functions in the innate and adaptive host immune responses against bacterial and 
fungal pathogens (5, 6) (see Table 1).
TABLe 1 | interaction of MCs with selected pathogens.
Pathogen Mast cell type Phagocytosis MCeTs Degranulation Reference
Staphylococcus aureus CBHMC √ no √ (7, 10)
HMC-1 √ (8, 9)
BMMCs √ (8)
Streptococcus pyogenes BMMC no √ √ (9)
HMC-1 no √ (9,11)
Pseudomonas aeruginosa Murine skin mast cells √ (12)
HMC-1 √ (9)
Citrobacter freundii CBHMC √ (7)
Klebsiella pneumoniae CBHMC √ (7)
Mouse lung mast cells in vivo √ (13)
Escherichia coli CBHMC √ (7)
Mouse lung mast cells in vivo √ (13,14)
Streptococcus faecium CBHMC √ (7)
Citrobacter rodentium BMMC AMP (14)
Enterococcus faecalis BMMC √ √ (15)
Candida albicans HMC-1, CBHMC √ √ (16)
Listeria monocytogenes BMMC no √ (17)
Salmonella typhimurium BMMC no √ (17)
Trichinella spiralis RBL-2H3, BMMC √ (18)
Leishmania major in vivo √ (19)
Helicobacter pylori BMMC, RBL-2H3 cells √ (20)
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MCs derive from hematopoietic progenitor cells and circulate 
in the blood until they reach their destination in the tissues, 
where they differentiate under the influence of growth factors 
and cytokines that ultimately determine their mature, long-
living phenotype (3). Different subsets of mature MCs have been 
described on the basis of functional, structural, and biochemical 
characteristics. Consequently, they are classified into at least two 
subgroups: mucosal MCs (MMCs) and connective tissue-type 
MCs (CTMCs) (3, 21). CTMCs typically reside in the skin and 
the peritoneal cavity. In contrast, MMCs are predominant in 
the mucosal layer of the intestine, where their numbers expand 
dramatically during e.g. parasitic infections (22, 23). Considering 
their long life span and phenotypic plasticity in the tissues, MCs 
contribution in chronic or acute infections is not fully understood 
(24). They are largely distributed near interfaces and potential 
entry sites of pathogens, such as the skin, the respiratory, and 
intestinal mucosa, and in close proximity to blood vessels and 
nerve cells (25, 26); therefore, MCs belong to the first immune 
cells, which come in contact with intruders. Since they orches-
trate the immune response by releasing various mediators, these 
long-living sentinel cells are crucial for the early recruitment of 
effector cells (24).
The main function of MCs is the release of inflammatory 
mediators such as proteases, cytokines, and chemokines by 
degranulation into the surrounding environment (22, 27). MCs 
are the only cell type known to pre-store TNF-α in their secretory 
granules, which can be released immediately upon activation 
e.g., by pathogens to initiate the early phase of the inflamma-
tory response (13, 28). Rocha-de-Souza et al. (10) showed that 
both alive and dead Staphylococcus (S.) aureus trigger TNF-α 
and IL-8 release from cord-blood-derived MCs in a time-
dependent manner. Nakamura et al. (29) published that culture 
supernatants of S. aureus contain potent MC degranulation 
activators. Biochemical analysis identified δ-toxin as the MC 
degranulation-inducing factor produced by S. aureus (30). 
Importantly, skin colonization with S. aureus, but not a mutant 
deficient in δ-toxin, promoted IgE and IL-4 production as well as 
skin diseases. Dietrich and colleagues showed that, in response 
to toll-like receptor (TLR) activation by the Gram-positive and 
-negative bacteria Listeria (L.) monocytogenes and Salmonella 
(S.) typhimurium, respectively, MCs elicit proinflammatory, but 
not type I IFN responses. In contrast, the response to viral infec-
tion is type I IFN dependent. Type I IFN signaling attenuates 
mast cell-dependent neutrophil recruitment that is required for 
bacterial clearance. Thus, the fact that MCs are equipped with 
the ability to release type I IFNs, but mount proinflammatory 
responses only upon TLR activation by bacteria, illustrates 
how MCs adjust their responses for optimal antibacterial and 
antiviral host defenses (17).
MCs are highly efficient effector cells that do not only release 
inflammatory mediators but also different antimicrobial peptides 
(AMPs), such as cathelicidins (31). These peptides have cationic 
and amphipathic properties that promote interactions with 
biological membranes and selectively kill a wide spectrum of 
microbes including bacteria, fungi, enveloped viruses, and pro-
tozoa (31). In vivo evidence from MC- and cathelicidin-deficient 
mouse models indicates that MC cathelicidins modulate tissue 
responsiveness to bacterial infection (32). The authors suggested 
that cathelicidins act as a natural antibiotic in MCs and may 
protect the skin from invasive group A Streptococcus (GAS) 
and S. aureus infection by direct bacterial killing. Moreover, the 
presence of cathelicidin in MCs may act to facilitate recruitment 
of neutrophils, thus indirectly providing enhanced protection 
against infection.
Despite the fact that the MCs release key inflammatory com-
pounds to modulate the immune response and to fight pathogens 
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with AMPs, the cells are additionally discussed to be able to elimi-
nate bacteria through an intracellular bactericidal mechanism 
similar to that of professional phagocytes (33). This mechanism 
seems to involve the endosome–lysosome pathway, in which 
the bacteria are killed through a combination of oxidative and 
non-oxidative killing systems (33). Arock and coworkers showed 
that human cord blood MCs (CBHMCs) are able to phagocytose 
and kill S. aureus, Streptococcus faecium, Klebsiella pneumoniae, 
Citrobacter freundii, and Escherichia (E.) coli by scanning and 
transmission electron microscopy and by quantifying bacterial 
survival in the presence of MCs compared with human umbili-
cal vein endothelial cells (HUVECs) (7). However, although 
the authors compared in  vitro results generated by different 
techniques with distinct pathogens, the data still remain short of 
a definitive proof in respect to the phagocytic response, since only 
total killing of bacteria in the presence of MCs was measured, 
and not a specific intracellular killing as normally performed by 
a gentamicin-protection assay. Finally, in contrast to the above 
hypothesis that MCs are able to phagocytose, Dietrich et  al. 
found only an exclusive extracellular interaction of MCs with L. 
monocytogenes or S. typhimurium using transmission electron 
microscopy (17).
Interestingly, Abel et al. (34) showed that MCs can internalize 
S. aureus without subsequent intracellular killing: the S. aureus 
strain SH100 was shown to be internalized in  vitro by murine 
and human MCs (primary murine bone marrow-derived MCs 
“BMMCs,” and human carcinoma MC line “HMC-1”) and by 
skin MCs during in vivo infections. MCs are utilized as a vehicle 
and a safe intracellular niche providing protection against other 
immune cells. Since the internalization efficiency depends on 
bacterial viability, the authors hypothesized that S. aureus may 
actively induce its uptake into MCs (34). In a recent follow-up 
publication, Goldmann and colleagues demonstrated enhanced 
S. aureus internalization by MCs based on the interaction of 
staphylococcal fibronectin-binding protein with host cellular 
integrin β1 (35). However, aside from the fact that S. aureus medi-
ates its own uptake into MCs to evade immune cell killing, MCs 
have been shown by several authors to exert a direct antimicrobial 
activity against this and other pathogens (7, 9, 34). Thus, it may 
be assumed that although MCs may act as a long-term staphy-
lococcal reservoir supporting persistence and chronic carriage, 
their activation can help to limit the early pathogen burden in 
the infected host.
In summary, MCs do not only orchestrate the early innate 
immune response through the release of mediators but they 
can also act antimicrobially in a pathogen-specific manner: 
extracellular by the release of antimicrobial products such as the 
cathelicidin-related AMPs (36) or intracellular by a phagocytic 
process. Finally, in 2008, an additional antimicrobial strategy 
was described for MCs, which was already known for neutro-
phils: the formation of antimicrobial mast cell extracellular traps 
(MCETs) (9).
MAST CeLL eXTRACeLLULAR TRAPS
Similar to the formation of neutrophil extracellular traps (NETs), 
MCs have also been shown to release their nuclear DNA and 
subsequently form antimicrobial MCETs that resemble extra-
cellular dendritic extensions (9). Interestingly, already in 1989, 
Trotter and colleagues mentioned that “superficial MCs have a 
smaller size and may be dendritic, with relatively few granules 
[…]” (37). However, the first experimental study on MCs and 
the formation of antimicrobial extracellular structures that 
strongly resembled the recently described NETs was published 
by von Köckritz-Blickwede et al. (9). The authors showed that 
even though MCs are unable to phagocytose Streptococcus (S.) 
pyogenes, they still can efficiently inhibit the growth by the release 
of MCETs. MCETs were found to support the extracellular kill-
ing of clumped bacteria that were not efficiently phagocytosed. 
Those MCET fibers are composed of DNA, histones, the MCs-
specific protease tryptase, and AMPs such as the cathelicidin 
AMP LL-37 (9).
Detailed information about the specific trigger that initiates 
MCET formation and the mechanisms regulating the removal of 
MCETs is still missing. However, literature clearly demonstrates 
that MCET formation is not the result of a passive release of 
DNA and granule proteins during cellular disintegration but, 
rather, an active and controlled process similar to that described 
for NETs (9). Similar to the observations of Fuchs et  al., who 
has implicated the production of reactive oxygen radicals and 
induction of cell death in the production of NETs, the forma-
tion of MCETs also strongly depends on the production of 
reactive oxygen species (ROS) and results in the death of the 
MC. Examination of stimulated MCs by electron and fluorescent 
microscopy confirmed that MCs undergo a similar mechanism 
of cell death as described for neutrophils when releasing NETs: 
MCET formation is associated with the disruption of the nuclear 
membrane before nuclear and granular components mix causing 
the death of the cell. Although ROS had been previously asso-
ciated with the induction of neutrophil apoptosis, Fuchs et  al. 
showed that the process accounting for NET formation is neither 
typical apoptosis nor necrosis, but rather a new form of ROS-
dependent cell death recently termed “NETosis” (38). Since this 
is also true for the formation of MCETs, this cell death was also 
named “ETosis” (39). The formation of MCETs can be greatly 
increased after stimulation of MCs with phorbol-12-myristate-
13-acetate (PMA), similar to NETs (40) or with the H2O2-
producing enzyme glucose oxidase, which is another indicator 
for the ROS-dependent MCET formation (9). Nevertheless, a 
key question still needs to be answered: why do MCs release 
MCETs although they are very well known as multifunctional 
long-living sentinel cells – what is worth dying for?
Several publications show that the formation of MCETs 
represents a novel mechanism by which MCs contribute to host 
defenses against bacterial and fungal pathogens. Interestingly, 
a diffused gradient of extracellular tryptase staining was often 
observed in areas with large numbers of bacteria during in vivo 
infections, which may indicate a massive release of this enzyme 
and possibly the not clearly visible but occurring formation of 
MCETs at the site of infection. The first specific bacterial protein 
identified to promote MCET production was the S. pyogenes sur-
face M1 protein (11). In quantitative assays, loss of M1 protein 
in the S. pyogenes ΔM1 mutant resulted in a significant decrease 
in the stimulation of NET as well as MCET release. Despite its 
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role in inducing ET formation, the authors found M1 protein 
promoting extracellular bacterial survival, at least in part due 
to resistance to the human AMP LL-37, an important effector 
of bacterial killing associated with extracellular traps. LL-37 
and its murine analog CRAMP are stored in MC granules; its 
expression is upregulated by LPS and found within the MCET 
structures where it contributes to the antimicrobial activity 
(9, 31). It has already been shown for neutrophils that LL-37 
significantly facilitated NET formation by primary human 
blood-derived neutrophils alone, in the presence of the classi-
cal chemical NET inducer PMA or in the presence of S. aureus 
(41). Nonetheless, the role of LL-37 in MCETs still needs to be 
investigated. Interestingly, Scheb-Wetzel et al. recently showed 
that MC release extracellular traps in response to Enterococcus 
(E.) faecalis, and the sensitivity of this pathogen to the antimi-
crobial effect of cathelicidin LL-37 indicated a potential major 
role for this AMP in the antimicrobial activity of MCs against E. 
faecalis (15). However, the level of MCET formation was not as 
pronounced as it has been reported for other pathogens such as 
S. pyogenes (9); therefore, killing of E. faecalis by MCETs cannot 
fully account for the antimicrobial effect of MCs observed in 
this study. This was further confirmed by the diminished, but 
still significant, antimicrobial effect of MCs after dismantling 
of the MCETs by nuclease treatment. The reason why only a 
certain percentage/population of MCs in the cultures released 
MCETs is not yet clear; eventually, this phenomenon may reflect 
heterogeneity in the physiological status of the MCs in culture; 
a similar phenomenon has been reported for extracellular trap 
formation by neutrophils (38).
Importantly, Lopes et al. (16) showed that MCs reveal an anti-
microbial activity against higher eukaryotes, namely the fungi 
Candida (C.) albicans. MCET release appears to be a mechanism 
of immune defense present in the MC toolbox against fungal 
pathogens, as both primary cells and HMC-1 release MCETs 
upon C. albicans stimulation. Interestingly, in contrast to bac-
teria (8, 9, 11, 15), C. albicans viability was not affected by the 
MC-derived DNA fibers and thus MCETs rather contribute to 
physical restriction of this fungal pathogens. Finally, the exact 
mechanism and the in vivo relevance of C. albicans-induced MC 
death need to be determined in further studies.
Similar to what has been shown for NETs, the formation 
of MCETs also seems to be associated with detrimental effects 
during health and diseases: a novel mechanistic stimulus 
for the release of extracellular traps in psoriasis lesions was 
described by Lin et  al. (42). It was demonstrated that IL-23 
and IL-1β increased the numbers of extracellular trap form-
ing cells e.g., neutrophils and MCs contributing to the release 
of the pathogenic cytokine IL-17. Nevertheless, the precise 
signaling mechanisms regulating this process remain to be 
defined. These observations support a model in which MCs 
and neutrophils play significant roles in the pathophysiology 
of psoriasis and potentially other autoinflammatory diseases 
driven by the IL-23-IL-17 axis. The authors suggested that a 
modulation of MC and neutrophil ETosis and release of IL-17 
could be used as a novel therapeutic mechanism of action for 
drugs targeting IL-23.
ReGULATiOn OF THe FORMATiOn OF 
MCeTs: COMPARiSOn wiTH neTs
It is still not entirely clear how the formation of MCETs is 
transcriptionally regulated. One factor identified to contribute 
to formation of MCETs is the central transcriptional regulator 
of the cellular response to hypoxic stress, namely the hypoxia-
inducible factor 1α (HIF-1α). Oxygen stress or hypoxia occurs in 
tissues during an infection, mostly, due to overconsumption of 
oxygen by pathogens and recruited immune cells. Importantly, 
HIF-1α activation or stabilization has been shown to support 
myeloid cell production of defense factors and improved bac-
tericidal capacity of immune cells (43, 44). In good correlation, 
Branitzki-Heinemann et al. (8) showed that MCET release was 
enhanced after MCs were treated with AKB-4924, a HIF-1α 
stabilizing agent. These MCETs were able to entrap and immo-
bilize S. aureus. Inhibition of phagocytosis did not alter the 
antimicrobial activity of MCs, whether or not HIF-1α activity 
was boosted with AKB-4924. Augmentation of HIF-1α-activity 
resulted in a boosting of the antimicrobial activity of human and 
murine MCs by inducing MCET formation. The results show for 
the first time that the extracellular antimicrobial activity of MCs 
is transcriptionally regulated and support the assumption that 
the transcription factor HIF-1α is not only a global player in the 
cellular response to low oxygen stress but also may, furthermore, 
act as a key regulator of the antimicrobial response of several 
immune cells including MCs (43–47). However, in contrast to 
MCs, the role of HIF-1α in the formation of extracellular traps 
produced by neutrophils remains to be elucidated. It has been 
shown that some well-known HIF-1α agonists including mimo-
sine and desferrioxamine (DFO) have an impact in neutrophil 
function. Mimosine has been proven to boost the bacterial killing 
by neutrophils. This effect was eliminated after DNAse treatment 
suggesting the involvement of NETs in the mimosine-mediated 
neutrophil killing activity (48). In good correlation to these 
data, DFO was recently described as a positive stimulus for NET 
formation (49). The authors hypothesized that stabilization of 
HIF-1α with agonists, such as DFO or mimosine, might facilitate 
the formation of NETs, which confirmed results from McInturff 
and coworkers showing that HIF-1α contributes to rapamycin-
induced NET formation in human neutrophils (50).
Although, MCETs and NETs share common characteristics, 
there are several cell type-specific differences. The formation of 
MCETs can be greatly increased after stimulation of MCs with 
PMA prior to infection (9), similar to NETs (40). But interest-
ingly, MCs release less MCETs stimulated with the same stimuli 
in comparison to neutrophils when studying the respective 
literature: whereas more than 90% of neutrophils undergo ETosis 
within 3 h upon stimulation with PMA (38), approximately only 
40% of MCs undergo ETosis after 6  h of stimulation with the 
same stimulus and concentration (9). Another important dif-
ference between MCs and neutrophils are their components, 
which are embedded in the DNA structures: elastase and MPO 
are essentially involved in the formation of NETs by degradation 
of histones and subsequent decondensation of chromatin; later 
both enzymes perform an antimicrobial role in NETs (51, 52). 
FiGURe 1 | Model for the formation of mast cell extracellular traps. (A) 1. MCs are activated by contact with microbial pathogens different stimuli such as 
IL-1β, IL-23, PMA, and glucose oxidase. Stimulation of MCs results in the activation of NADPH oxidases and the formation of reactive oxygen species (ROS). 2. The 
nuclear membrane disrupts and the chromatin decondensates. 3. The nuclear contents mix with cytoplasmic and granular proteins. 4. Nuclear and granular 
components are released by the cell generating extracellular traps, which have the ability to entrap and/or kill different microbes, while also enhancing 
proinflammatory innate immune responses. (B) PMA-stimulated MCETs of BMMCs [live dead staining, red: dead cells (loss of integrity of the plasma membrane) and 
extracellular DNA, green: living cells (intracellular esterase activity)]. *Differences compared with neutrophil extracellular traps (NETs); 1Role of HlF-lα in the formation 
of NETs in contrast to MCETs is not yet exactly clarified and *2Tryptase is unique for MCETs.
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In MCs, elastase and myeloperoxidase are not even expressed 
(53). Until now, it is unclear if, for example, MC-specific tryptase, 
which has also been shown as a component of MCETs (9), has 
similar functions in MCs.
In neutrophils, it has been additionally demonstrated that these 
cells can release ETs in response to infection, while remaining in a 
viable status, confirmed in vivo in a murine S. aureus skin infec-
tion model (54, 55). Formation of extracellular traps by viable 
eosinophils and basophils was also shown in response to E. coli 
and S. aureus (56, 57) and subsequent release of mitochondrial 
DNA (54). However, if a similar phenomenon also occurs in MCs 
is still unknown. Interestingly, in Figure 1, we can identify viable 
MCs in close contact to MCETs after treatment of MCs with PMA 
for 3 h. Thus, further investigations are needed to determine if 
MCs are also able to release extracellular traps in a viable status.
COnCLUSiOn
In summary, the actual literature assumes that MCET formation 
is not the result of passive release of DNA and granular proteins 
during cellular disintegration, but rather an active and controlled 
process in response to specific stimulation. The extracellular 
structures act antimicrobially through a combination of direct 
killing of the entrapped pathogen or by its physical immobili-
zation that enables the recruited effector cells to eliminate the 
pathogen. Both aspects may have a significant impact on the dis-
ease outcome. The fact that aggregated NETs limit inflammation 
by degrading cytokines and chemokines has already been shown 
(58). If MCET formation may decrease uncontrolled mast cell 
degranulation and subsequent dissemination of chemokines and 
cytokines during an acute overwhelming infection or autoim-
mune disease, which could lead to tissue damage, inflammation, 
and nerve cell activation with a potentially negative impact on 
the organism needs further investigation (59, 60). In any case, a 
plausible answer to the question “why do these long-living cells 
form MCETs” could be: MCETs are of particular importance 
in the direct and indirect antimicrobial activity against various 
pathogens; additionally, MCET formation may help to avoid or 
minimize affliction of the host by restricting the inflammatory 
responses.
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